sulfotransferase family 1E member 1Genealiases: EST · EST-1 · ST1E1 · STE
Q-omics provides the consensus-scored SULT1E1 profile across patient tissues and cancer cell-line models. SULT1E1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SULT1E1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, SULT1E1 RNA expression shows 10,791 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KICH, and TGCT as cancer lineages where SULT1E1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT1E1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT1E1 survival associations across molecular data types. SULT1E1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT1E1 RNA expression–survival associations across cancer types. High SULT1E1 expression shows unfavorable associations in MESO, KIRP, PAAD, LGG and CHOL, but favorable associations in CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SULT1E1 RNA expression.
This table summarizes SULT1E1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SULT1E1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT1E1 shows lower tumor expression in KICH, LUAD, LIHC and CHOL and higher tumor expression in BLCA and HNSC. The KICH box plot shows higher SULT1E1 RNA expression in normal versus tumor tissue (log2 FC = −0.402, t-test p < 0.001).
This table shows molecular features associated with SULT1E1 in patient tissues and cancer cell lines. In patient samples, SULT1E1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SULT1E1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LIVER.
